A meta-analysis of the vascular-related safety profile and efficacy of alpha-adrenergic blockers for symptoms related to benign prostatic hyperplasia.
作者： J. C. Nickel , S. Sander , T. D. Moon
DOI: 10.1111/J.1742-1241.2008.01880.X
关键词: Pathology 、 Alpha-adrenergic blockers 、 Hyperplasia 、 Urology 、 Meta analisis 、 Blood vessel 、 Meta-analysis 、 Adrenergic alpha-Antagonists 、 Safety profile 、 α adrenergic receptors 、 Medicine
摘要: Objectives: To evaluate the safety profile and efficacy of α1‐adrenergic receptor blockers (A1Bs) currently prescribed for benign prostatic hyperplasia (BPH). Data sources: A systematic …
sci-hub.se 参考文章(52)
Herbert Lepor, Long-Term Evaluation of Tamsulosin in Benign Prostatic Hyperplasia: Placebo-Controlled, Double-Blind Extension of Phase III Trial Urology. ,vol. 51, pp. 901- 906 ,(1998) , 10.1016/S0090-4295(98)00127-7
Ahmed Fawzy, Karl Braun, George P. Lewis, Michael Gaffney, Kathleen Ice, , Doxazosin in the Treatment of Benign Prostatic Hyperplasia in Normotensive Patients: A Multicenter Study * The Journal of Urology. ,vol. 154, pp. 105- 109 ,(1995) , 10.1016/S0022-5347(01)67240-9
Charlene D. Richardson, Craig F. Donatucci, Stella O. Page, Katrina H. Wilson, Debra A. Schwinn, Pharmacology of tamsulosin: Saturation-binding isotherms and competition analysis using cloned α1-adrenergic receptor subtypes The Prostate. ,vol. 33, pp. 55- 59 ,(1997) , 10.1002/(SICI)1097-0045(19970915)33:1<55::AID-PROS9>3.0.CO;2-8
H. LEPOR, A. LADDU, Terazosin in the treatment of benign prostatic hyperplasia : the United States experience BJUI. ,vol. 70, pp. 2- 9 ,(1992) , 10.1111/J.1464-410X.1992.TB15860.X
Jennifer C Spalton, Norman J Maitland, R.Michael Sharrand, Insulin-like growth factor 1, the protein kinase B pathway and the progression to metastasis of prostate cancer European Urology Supplements. ,vol. 2, pp. 33- ,(2003) , 10.1016/S1569-9056(03)90412-X
P. ABRAMS, C.C. SCHULMAN, S. VAAGE, Tamsulosin, a selective α1c‐adrenoceptor* antagonist: a randomized, controlled trial in patients with benign prostatic ‘obstruction’ (symptomatic BPH) BJUI. ,vol. 76, pp. 325- 336 ,(1995) , 10.1111/J.1464-410X.1995.TB07709.X
Alejandro R. Jadad, R.Andrew Moore, Dawn Carroll, Crispin Jenkinson, D.John M. Reynolds, David J. Gavaghan, Henry J. McQuay, Assessing the quality of reports of randomized clinical trials : is blinding necessary? Controlled Clinical Trials. ,vol. 17, pp. 1- 12 ,(1996) , 10.1016/0197-2456(95)00134-4
Herbert Lepor, Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia Urology. ,vol. 45, pp. 406- 413 ,(1995) , 10.1016/S0090-4295(99)80008-9
Rudolf Foglar, Katsushi Shibata, Kuniko Horie, Akira Hirasawa, Gozoh Tsujimoto, Use of recombinant α1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy European Journal of Pharmacology. ,vol. 288, pp. 201- 207 ,(1995) , 10.1016/0922-4106(95)90195-7
Christopher R. Chapple, Salman H. Al-Shukri, Bernard Gattegno, Simon Holmes, José M. Martínez-Sagarra, Roberto M. Scarpa, Oncko B. van Vierssen Trip, Viktor Vik, Ingrid van der Putten-Slob, Tamsulosin Oral Controlled Absorption System (OCAS) in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): Efficacy and Tolerability in a Placebo and Active Comparator Controlled Phase 3a Study European Urology Supplements. ,vol. 4, pp. 33- 44 ,(2005) , 10.1016/J.EURSUP.2004.10.010